Abstract

Polyclonal antibodies are popular research reagents for their high sensitivity and robust cross-platform performance. But few companies consider them viable for therapeutic applications as they are almost impossible to characterize. Additionally, they suffer from a lack of reproducibility and limited supply.

Monoclonal antibodies (mAbs) can be reliably characterized and produced for therapeutic applications, but are more costly to discover and develop. Rapid Novor’s REpAb technology can overcome these limitations by capturing the sequences of the most abundant IgG in a pAb and enabling indefinite antibody production. Here we report the first successful conversion of a goat polyclonal antibody into a cocktail of recombinant mAbs using only the pAb protein sample.

Related Posts

Enriching Engineered T Cells with Antibody Sequencing & Modulation

May 10th, 2022

Breakthrough Bispecific Antibody R&D Techniques

March 29th, 2022

Species Agnostic Antibody Sequencing & Discovery in Veterinary Medicine R&D

February 20th, 2022

Why Antibody Characterization Needs An Overhaul

February 20th, 2022

Leveraging the Power of Next Generation Protein Sequencing to Shape Tomorrow’s In Vitro Diagnostics

February 3rd, 2022

Why Is Sequence Blindness Acceptable with Antibodies?

January 30th, 2022

Newsletter for All Things Protein Sequencing

Breakthrough Bispecific Antibody R&D Techniques, Apr 20 11:00am EST.

Talk to Our Scientists.

We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 5000 antibodies and we are eager to help you.